Last reviewed · How we verify
SR-878
At a glance
| Generic name | SR-878 |
|---|---|
| Sponsor | SciRhom GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Safety and Tolerabiliy of SR-878 in Patients With Rheumatoid Arthritis (PHASE1)
- Study Investigating the Safety, Tolerability and Blood Concentration of the Substance SR-878 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SR-878 CI brief — competitive landscape report
- SR-878 updates RSS · CI watch RSS
- SciRhom GmbH portfolio CI